Literature DB >> 12458919

Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.

.   

Abstract

In December 2000, the Advisory Committee on Immunization Practices (ACIP) released its recommendations for using anthrax vaccine in the United States. Because of recent terrorist attacks involving the intentional exposure of U.S. civilians to Bacillus anthracis spores and concerns that the current anthrax vaccine supply is limited, ACIP developed supplemental recommendations on using anthrax vaccine in response to terrorism. These recommendations supplement the previous ACIP statement in three areas: use of anthrax vaccine for pre-exposure vaccination in the U.S. civilian population, the prevention of anthrax by postexposure prophylaxis (PEP), and recommendations for additional research related to using antimicrobial agents and anthrax vaccine for preventing anthrax

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458919

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  10 in total

1.  Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Robert Bollinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

2.  The anthrax vaccine and research: reactions from postal workers and public health professionals.

Authors:  Sandra Crouse Quinn; Tammy Thomas; Supriya Kumar
Journal:  Biosecur Bioterror       Date:  2008-12

3.  The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed.

Authors:  N M Pajewski; S D Parker; G A Poland; I G Ovsyannikova; W Song; K Zhang; B A McKinney; V S Pankratz; J C Edberg; R P Kimberly; R M Jacobson; J Tang; R A Kaslow
Journal:  Genes Immun       Date:  2011-03-03       Impact factor: 2.676

Review 4.  Anthrax infection.

Authors:  Daniel A Sweeney; Caitlin W Hicks; Xizhong Cui; Yan Li; Peter Q Eichacker
Journal:  Am J Respir Crit Care Med       Date:  2011-08-18       Impact factor: 21.405

Review 5.  An overview of anthrax infection including the recently identified form of disease in injection drug users.

Authors:  Caitlin W Hicks; Daniel A Sweeney; Xizhong Cui; Yan Li; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2012-04-24       Impact factor: 17.440

6.  Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.

Authors:  Elizabeth K Leffel; James S Bourdage; E Diane Williamson; Matthew Duchars; Thomas R Fuerst; Peter C Fusco
Journal:  Clin Vaccine Immunol       Date:  2012-06-13

7.  Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.

Authors:  Demetrios N Kyriacou; Debra Dobrez; Jorge P Parada; Justin M Steinberg; Adam Kahn; Charles L Bennett; Brian P Schmitt
Journal:  Biosecur Bioterror       Date:  2012-07-30

8.  Differential willingness to undergo smallpox vaccination among African-American and white individuals.

Authors:  Ellyn Micco; Andrea D Gurmankin; Katrina Armstrong
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 5.128

9.  Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques.

Authors:  Anne E Boyer; Conrad P Quinn; Alex R Hoffmaster; Thomas R Kozel; Elke Saile; Chung K Marston; Ann Percival; Brian D Plikaytis; Adrian R Woolfitt; Maribel Gallegos; Patrick Sabourin; Lisa G McWilliams; James L Pirkle; John R Barr
Journal:  Infect Immun       Date:  2009-06-08       Impact factor: 3.441

10.  Conference report on public health and clinical guidelines for anthrax.

Authors:  Eric Jacob Stern; Kristin Broome Uhde; Sean Vincent Shadomy; Nancy Messonnier
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.